Eli Lilly Korea has launched Ebglyss, a biologic therapy designed to treat moderate-to-severe atopic dermatitis. This innovative treatment, which comes as a 250 mg pre-filled autoinjector containing lebrikizumab, specifically targets interleukin-13 (IL-13), a cytokine closely associated with the condition. Approved by Korea’s Ministry of Food and Drug Safety in August last year, Ebglyss is intended for adults and adolescents aged 12 and older (weighing at least 40 kilograms) whose symptoms are not adequately managed with topical therapies or for whom such treatments are not suitable.
Ebglyss offers a convenient dosing regimen, starting with a 16-week initial treatment followed by a maintenance dose of 250 mg administered every four weeks for those who respond well. Its approval was backed by robust data from three phase 3 clinical trials—ADvocate-1, ADvocate-2, and ADhere—involving over 1,000 participants. The trials demonstrated significant efficacy, with 16-week response rates (EASI-75) of up to 58.8% compared to 16.2% for placebo, and long-term improvements reaching 81.7% after 52 weeks of maintenance therapy.
Adverse events were minimal and manageable, with the most common issues being conjunctivitis, injection site reactions, allergic conjunctivitis, and dry eye. The majority of these events were mild to moderate and did not lead to treatment discontinuation, even after one year of use. With its strong clinical performance and safety profile, Ebglyss is poised to provide an effective and convenient treatment option for patients struggling with the challenges of atopic dermatitis.
